Skip to main content
SpringerLink
Log in

Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report

  • case report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

A 68-year-old man was diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Immunochemotherapy with carboplatin, paclitaxel, and pembrolizumab followed by maintenance therapy with pembrolizumab resulted in clinically meaningful remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, Kim JY, Del Priore I, Schoenfeld AJ, Miller M, Kartha VK, Westcott PMK, Sánchez-Rivera FJ, Meli K, Gupta M, Bronson RT, Riely GJ, Rekhtman N, Rudin CM, Kim CF, Regev A, Buenrostro JD, Jacks T. Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discov. 2022;12(2):562–85. https://doi.org/10.1158/2159-8290.CD-21-0248.

    Article  CAS  PubMed  Google Scholar 

  2. Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231–47. https://doi.org/10.1016/j.jtho.2019.10.023.

    Article  CAS  PubMed  Google Scholar 

  3. Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, Daneshbod Y, Chang J, Sauter JL, Beras A, Ladanyi M, Jacks T, Rudin CM, Taylor BS, Donoghue MTA, Heller G, Hellmann MD, Rekhtman N, Riely GJ. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 2020;26(21):5701–8. https://doi.org/10.1158/1078-0432.CCR-20-1825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM, KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.

    Article  CAS  PubMed  Google Scholar 

  5. Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. Thorac Cancer. 2019;10(12):2312–5. https://doi.org/10.1111/1759-7714.13215. Erratum in: Thorac Cancer. 2020 Dec;11(12):3645.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol. 2019;30(8):1401–3. https://doi.org/10.1093/annonc/mdz160.

    Article  CAS  PubMed  Google Scholar 

  7. Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clin Lung Cancer. 2022;23(5):386–92. https://doi.org/10.1016/j.cllc.2022.03.005.

    Article  CAS  PubMed  Google Scholar 

  8. Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer. 2019;132:59–64. https://doi.org/10.1016/j.lungcan.2019.03.029.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Haematology with Palliative Care, Clinic Ottakring, Montlearstraße 37, Pavillon 23, Vienna, Austria

    Clemens Petrasch MD, Simon Udovica MD, Frédéric Witte MD, Wolfgang Hilbe MD & Andrea Kaufmann-Keck MD

  2. Institute of Pathology, Medical University Graz, Graz, Austria

    Bernadette Liegl-Atzwanger MD

  3. Department of Pathology and Microbiology, Clinic Ottakring, Vienna, Austria

    Wolfgang Pokieser MD

  4. Department of Nuclear Medicine and PET CT, Clinic Ottakring, Vienna, Austria

    Siroos Mirzaei MD

Authors
  1. Clemens Petrasch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon Udovica MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frédéric Witte MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernadette Liegl-Atzwanger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Pokieser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Siroos Mirzaei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wolfgang Hilbe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrea Kaufmann-Keck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Petrasch MD.

Ethics declarations

Conflict of interest

C. Petrasch: Personal fee: MSD. S. Udovica, F. Witte, B. Liegl-Atzwanger, W. Pokieser, S. Mirzaei, W. Hilbe and A. Kaufmann-Keck declare that they have no competing interests.

Ethical standards

Considering the nature of this report no formal ethics committee approval was required. Informed consent was obtained from all patients for being included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrasch, C., Udovica, S., Witte, F. et al. Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report. memo 16, 122–124 (2023). https://doi.org/10.1007/s12254-023-00880-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00880-7

Keywords

Search

Navigation